全球CRO排名公布!药明系拿下第三

同壁财经
10 Jun

据医药魔方数据,在全球CRO企业中,药明系(合并药明康德、药明生物、药明合联)2024年收入87.01亿美元,位列第3;第1、第2名分别为IQVIA(艾昆纬)、Thermo(赛默飞)。药明系凭借大而全的业务布局,占据榜单前列。展望后市,借鉴全球CRO巨头的发展经验,中国CRO行业或能更好地融入全球生物医药产业链。恒生医药ETF(159892)聚焦创新药产业链上中下游,持仓药明康德、药明生物、...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10